Cognition Therapeutics announces Phase 2 ‘START’ study reached 75% enrollment

Cognition Therapeutics (CGTX) announced that the Phase 2 ‘START’ Study has reached the 75% enrollment mark. The START Study is enrolling approximately 540 individuals with mild cognitive impairment, MCI, and early Alzheimer’s disease who will be treated with zervimesine or placebo for 18 months. Cognition is conducting the study in collaboration with the Alzheimer’s Clinical Trials Consortium, ACTC, with funding from the National Institute of Aging, NIA, at the National Institutes of Health.